nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—ABCC5—Cisplatin—testicular cancer	0.19	0.531	CbGbCtD
Dipyridamole—ABCC4—Methotrexate—testicular cancer	0.0594	0.166	CbGbCtD
Dipyridamole—ABCB1—Dactinomycin—testicular cancer	0.0309	0.0861	CbGbCtD
Dipyridamole—ABCB1—Vinblastine—testicular cancer	0.0194	0.054	CbGbCtD
Dipyridamole—ABCB1—Cisplatin—testicular cancer	0.0177	0.0495	CbGbCtD
Dipyridamole—ABCB1—Etoposide—testicular cancer	0.0174	0.0486	CbGbCtD
Dipyridamole—ABCB1—Doxorubicin—testicular cancer	0.0119	0.0332	CbGbCtD
Dipyridamole—ABCB1—Methotrexate—testicular cancer	0.0115	0.0321	CbGbCtD
Dipyridamole—PDE6A—testis—testicular cancer	0.00807	0.0471	CbGeAlD
Dipyridamole—PRUNE—female gonad—testicular cancer	0.00576	0.0336	CbGeAlD
Dipyridamole—PDE1C—testis—testicular cancer	0.00566	0.033	CbGeAlD
Dipyridamole—PDE2A—seminal vesicle—testicular cancer	0.00563	0.0328	CbGeAlD
Dipyridamole—PDE6D—female gonad—testicular cancer	0.00556	0.0324	CbGeAlD
Dipyridamole—PRUNE—testis—testicular cancer	0.00511	0.0298	CbGeAlD
Dipyridamole—PDE6D—testis—testicular cancer	0.00493	0.0288	CbGeAlD
Dipyridamole—PDE6B—testis—testicular cancer	0.00485	0.0283	CbGeAlD
Dipyridamole—PDE8A—seminal vesicle—testicular cancer	0.00483	0.0282	CbGeAlD
Dipyridamole—PDE11A—testis—testicular cancer	0.00451	0.0263	CbGeAlD
Dipyridamole—PDE6G—testis—testicular cancer	0.00434	0.0253	CbGeAlD
Dipyridamole—PDE1C—lymph node—testicular cancer	0.0041	0.0239	CbGeAlD
Dipyridamole—PDE1B—gonad—testicular cancer	0.00403	0.0235	CbGeAlD
Dipyridamole—PDE8B—gonad—testicular cancer	0.00388	0.0226	CbGeAlD
Dipyridamole—PRUNE—lymph node—testicular cancer	0.0037	0.0216	CbGeAlD
Dipyridamole—PDE6D—lymph node—testicular cancer	0.00358	0.0209	CbGeAlD
Dipyridamole—PDE7B—testis—testicular cancer	0.00351	0.0205	CbGeAlD
Dipyridamole—PRUNE—Vinorelbine—Vinblastine—testicular cancer	0.0034	0.35	CbGdCrCtD
Dipyridamole—PRUNE—Podofilox—Etoposide—testicular cancer	0.0034	0.35	CbGdCrCtD
Dipyridamole—PDE1A—gonad—testicular cancer	0.00338	0.0197	CbGeAlD
Dipyridamole—PDE10A—female gonad—testicular cancer	0.00331	0.0193	CbGeAlD
Dipyridamole—PDE6G—lymph node—testicular cancer	0.00315	0.0184	CbGeAlD
Dipyridamole—PDE2A—testis—testicular cancer	0.00293	0.0171	CbGeAlD
Dipyridamole—PDE10A—testis—testicular cancer	0.00293	0.0171	CbGeAlD
Dipyridamole—PDE1B—testis—testicular cancer	0.00291	0.017	CbGeAlD
Dipyridamole—PRUNE—Vincristine—Vinblastine—testicular cancer	0.00291	0.3	CbGdCrCtD
Dipyridamole—PDE8A—female gonad—testicular cancer	0.00284	0.0166	CbGeAlD
Dipyridamole—PDE8B—testis—testicular cancer	0.0028	0.0163	CbGeAlD
Dipyridamole—PDE1A—female gonad—testicular cancer	0.00275	0.016	CbGeAlD
Dipyridamole—PDE3B—testis—testicular cancer	0.00273	0.0159	CbGeAlD
Dipyridamole—PDE7B—lymph node—testicular cancer	0.00255	0.0149	CbGeAlD
Dipyridamole—PDE8A—testis—testicular cancer	0.00252	0.0147	CbGeAlD
Dipyridamole—PDE1A—testis—testicular cancer	0.00244	0.0142	CbGeAlD
Dipyridamole—PDE5A—gonad—testicular cancer	0.00238	0.0139	CbGeAlD
Dipyridamole—PDE4A—female gonad—testicular cancer	0.00228	0.0133	CbGeAlD
Dipyridamole—PDE2A—lymph node—testicular cancer	0.00213	0.0124	CbGeAlD
Dipyridamole—PDE10A—lymph node—testicular cancer	0.00213	0.0124	CbGeAlD
Dipyridamole—PDE1B—lymph node—testicular cancer	0.00211	0.0123	CbGeAlD
Dipyridamole—ADA—testis—testicular cancer	0.00207	0.0121	CbGeAlD
Dipyridamole—PDE8B—lymph node—testicular cancer	0.00203	0.0118	CbGeAlD
Dipyridamole—PDE4A—testis—testicular cancer	0.00202	0.0118	CbGeAlD
Dipyridamole—SLC29A1—gonad—testicular cancer	0.002	0.0117	CbGeAlD
Dipyridamole—PDE3B—lymph node—testicular cancer	0.00198	0.0116	CbGeAlD
Dipyridamole—PDE5A—female gonad—testicular cancer	0.00194	0.0113	CbGeAlD
Dipyridamole—PDE3A—female gonad—testicular cancer	0.00188	0.011	CbGeAlD
Dipyridamole—PDE8A—lymph node—testicular cancer	0.00182	0.0106	CbGeAlD
Dipyridamole—ABCC5—female gonad—testicular cancer	0.00177	0.0103	CbGeAlD
Dipyridamole—PDE1A—lymph node—testicular cancer	0.00177	0.0103	CbGeAlD
Dipyridamole—PDE5A—testis—testicular cancer	0.00172	0.01	CbGeAlD
Dipyridamole—PDE3A—testis—testicular cancer	0.00167	0.00974	CbGeAlD
Dipyridamole—SLC29A1—female gonad—testicular cancer	0.00163	0.00948	CbGeAlD
Dipyridamole—ABCC5—testis—testicular cancer	0.00157	0.00916	CbGeAlD
Dipyridamole—ADA—lymph node—testicular cancer	0.0015	0.00876	CbGeAlD
Dipyridamole—PDE4A—lymph node—testicular cancer	0.00146	0.00853	CbGeAlD
Dipyridamole—SLC29A1—testis—testicular cancer	0.00144	0.00841	CbGeAlD
Dipyridamole—PDE5A—lymph node—testicular cancer	0.00124	0.00726	CbGeAlD
Dipyridamole—ABCC4—female gonad—testicular cancer	0.00123	0.00716	CbGeAlD
Dipyridamole—PDE3A—lymph node—testicular cancer	0.00121	0.00706	CbGeAlD
Dipyridamole—ABCC5—lymph node—testicular cancer	0.00114	0.00664	CbGeAlD
Dipyridamole—ABCC4—testis—testicular cancer	0.00109	0.00635	CbGeAlD
Dipyridamole—SLC29A1—lymph node—testicular cancer	0.00104	0.00609	CbGeAlD
Dipyridamole—ABCC4—lymph node—testicular cancer	0.000789	0.0046	CbGeAlD
Dipyridamole—ABCB1—embryo—testicular cancer	0.000774	0.00452	CbGeAlD
Dipyridamole—ABCB1—seminal vesicle—testicular cancer	0.000727	0.00424	CbGeAlD
Dipyridamole—PDE1C—DAP12 interactions—KIT—testicular cancer	0.000645	0.0032	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by NGF—KITLG—testicular cancer	0.000644	0.0032	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by EGFR—KIT—testicular cancer	0.000639	0.00317	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling by Wnt—H2AFZ—testicular cancer	0.000636	0.00316	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000634	0.00315	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by PDGF—KIT—testicular cancer	0.000631	0.00313	CbGpPWpGaD
Dipyridamole—PDE1C—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000622	0.00309	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000613	0.00304	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—INSL3—testicular cancer	0.000611	0.00304	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—INSL3—testicular cancer	0.000611	0.00304	CbGpPWpGaD
Dipyridamole—PDE1C—Innate Immune System—BCL10—testicular cancer	0.000609	0.00302	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—INSL3—testicular cancer	0.000596	0.00296	CbGpPWpGaD
Dipyridamole—PDE1A—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000578	0.00287	CbGpPWpGaD
Dipyridamole—PDE1C—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000571	0.00284	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—INSL3—testicular cancer	0.000545	0.00271	CbGpPWpGaD
Dipyridamole—PDE3B—GPCR downstream signaling—INSL3—testicular cancer	0.000545	0.0027	CbGpPWpGaD
Dipyridamole—PDE1A—Downstream signal transduction—KITLG—testicular cancer	0.000543	0.0027	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by FGFR—KITLG—testicular cancer	0.000541	0.00268	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by ERBB2—KITLG—testicular cancer	0.000538	0.00267	CbGpPWpGaD
Dipyridamole—PDE1A—DAP12 signaling—KITLG—testicular cancer	0.000535	0.00266	CbGpPWpGaD
Dipyridamole—ABCC4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000534	0.00265	CbGpPWpGaD
Dipyridamole—PDE1B—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000529	0.00262	CbGpPWpGaD
Dipyridamole—ABCB1—gonad—testicular cancer	0.000526	0.00307	CbGeAlD
Dipyridamole—PDE4A—GPCR downstream signaling—INSL3—testicular cancer	0.00051	0.00253	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—INSL3—testicular cancer	0.000507	0.00252	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—INSL3—testicular cancer	0.000507	0.00252	CbGpPWpGaD
Dipyridamole—PDE1A—DAP12 interactions—KITLG—testicular cancer	0.000504	0.0025	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by FGFR in disease—KITLG—testicular cancer	0.000504	0.0025	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by EGFR—KITLG—testicular cancer	0.000499	0.00248	CbGpPWpGaD
Dipyridamole—PDE1B—Downstream signal transduction—KITLG—testicular cancer	0.000497	0.00247	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—INSL3—testicular cancer	0.000496	0.00246	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000495	0.00246	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—INSL3—testicular cancer	0.000495	0.00246	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by FGFR—KITLG—testicular cancer	0.000494	0.00245	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by PDGF—KITLG—testicular cancer	0.000492	0.00245	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by ERBB2—KITLG—testicular cancer	0.000492	0.00244	CbGpPWpGaD
Dipyridamole—PDE1B—DAP12 signaling—KITLG—testicular cancer	0.00049	0.00243	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by NGF—FGFR3—testicular cancer	0.000479	0.00238	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—INSL3—testicular cancer	0.00047	0.00233	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—INSL3—testicular cancer	0.000466	0.00232	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—INSL3—testicular cancer	0.000463	0.0023	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—INSL3—testicular cancer	0.000463	0.0023	CbGpPWpGaD
Dipyridamole—PDE1B—DAP12 interactions—KITLG—testicular cancer	0.000461	0.00229	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by FGFR in disease—KITLG—testicular cancer	0.000461	0.00229	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by EGFR—KITLG—testicular cancer	0.000456	0.00227	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000452	0.00225	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—INSL3—testicular cancer	0.000452	0.00224	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—INSL3—testicular cancer	0.00045	0.00224	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by PDGF—KITLG—testicular cancer	0.00045	0.00224	CbGpPWpGaD
Dipyridamole—PDE1A—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000446	0.00221	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by NGF—KIT—testicular cancer	0.000439	0.00218	CbGpPWpGaD
Dipyridamole—PDE1A—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.00043	0.00213	CbGpPWpGaD
Dipyridamole—ABCB1—female gonad—testicular cancer	0.000427	0.00249	CbGeAlD
Dipyridamole—PDE1B—GPCR downstream signaling—INSL3—testicular cancer	0.000427	0.00212	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—INSL3—testicular cancer	0.000424	0.0021	CbGpPWpGaD
Dipyridamole—PDE1B—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000408	0.00203	CbGpPWpGaD
Dipyridamole—PDE1A—Downstream signal transduction—FGFR3—testicular cancer	0.000404	0.002	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by FGFR—FGFR3—testicular cancer	0.000402	0.00199	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by ERBB2—FGFR3—testicular cancer	0.0004	0.00198	CbGpPWpGaD
Dipyridamole—PDE1A—DAP12 signaling—FGFR3—testicular cancer	0.000398	0.00198	CbGpPWpGaD
Dipyridamole—PDE1A—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000394	0.00196	CbGpPWpGaD
Dipyridamole—PDE1B—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.000393	0.00195	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—INSL3—testicular cancer	0.000387	0.00192	CbGpPWpGaD
Dipyridamole—ABCB1—testis—testicular cancer	0.000379	0.00221	CbGeAlD
Dipyridamole—PDE1A—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000374	0.00186	CbGpPWpGaD
Dipyridamole—PDE1A—DAP12 interactions—FGFR3—testicular cancer	0.000374	0.00186	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by EGFR—FGFR3—testicular cancer	0.000371	0.00184	CbGpPWpGaD
Dipyridamole—PDE1A—Downstream signal transduction—KIT—testicular cancer	0.000371	0.00184	CbGpPWpGaD
Dipyridamole—PDE1B—Downstream signal transduction—FGFR3—testicular cancer	0.000369	0.00183	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by FGFR—KIT—testicular cancer	0.000369	0.00183	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000368	0.00183	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by FGFR—FGFR3—testicular cancer	0.000367	0.00182	CbGpPWpGaD
Dipyridamole—PDE1C—Innate Immune System—KITLG—testicular cancer	0.000367	0.00182	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by ERBB2—KIT—testicular cancer	0.000367	0.00182	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by PDGF—FGFR3—testicular cancer	0.000366	0.00182	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by ERBB2—FGFR3—testicular cancer	0.000366	0.00182	CbGpPWpGaD
Dipyridamole—PDE1A—DAP12 signaling—KIT—testicular cancer	0.000365	0.00181	CbGpPWpGaD
Dipyridamole—PDE1B—DAP12 signaling—FGFR3—testicular cancer	0.000364	0.00181	CbGpPWpGaD
Dipyridamole—PDE1B—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000361	0.00179	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—BCL10—testicular cancer	0.000355	0.00176	CbGpPWpGaD
Dipyridamole—PDE1A—DAP12 interactions—KIT—testicular cancer	0.000344	0.00171	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by FGFR in disease—KIT—testicular cancer	0.000344	0.00171	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by NGF—KITLG—testicular cancer	0.000343	0.0017	CbGpPWpGaD
Dipyridamole—PDE1B—DAP12 interactions—FGFR3—testicular cancer	0.000342	0.0017	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000342	0.0017	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by EGFR—KIT—testicular cancer	0.000341	0.00169	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by EGFR—FGFR3—testicular cancer	0.000339	0.00168	CbGpPWpGaD
Dipyridamole—PDE1B—Downstream signal transduction—KIT—testicular cancer	0.000339	0.00168	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000338	0.00168	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by FGFR—KIT—testicular cancer	0.000337	0.00168	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000336	0.00167	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by PDGF—KIT—testicular cancer	0.000336	0.00167	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by ERBB2—KIT—testicular cancer	0.000336	0.00167	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by PDGF—FGFR3—testicular cancer	0.000335	0.00166	CbGpPWpGaD
Dipyridamole—PDE1B—DAP12 signaling—KIT—testicular cancer	0.000334	0.00166	CbGpPWpGaD
Dipyridamole—Thrombocytopenia—Etoposide—testicular cancer	0.000332	0.00128	CcSEcCtD
Dipyridamole—PDE1A—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000331	0.00165	CbGpPWpGaD
Dipyridamole—Tachycardia—Etoposide—testicular cancer	0.000331	0.00128	CcSEcCtD
Dipyridamole—Dyspnoea—Cisplatin—testicular cancer	0.00033	0.00128	CcSEcCtD
Dipyridamole—Skin disorder—Etoposide—testicular cancer	0.00033	0.00127	CcSEcCtD
Dipyridamole—PDE6A—Disease—H2AFZ—testicular cancer	0.000329	0.00163	CbGpPWpGaD
Dipyridamole—PDE6B—Disease—H2AFZ—testicular cancer	0.000329	0.00163	CbGpPWpGaD
Dipyridamole—Hyperhidrosis—Etoposide—testicular cancer	0.000328	0.00127	CcSEcCtD
Dipyridamole—Abdominal pain upper—Doxorubicin—testicular cancer	0.000327	0.00126	CcSEcCtD
Dipyridamole—Orthostatic hypotension—Doxorubicin—testicular cancer	0.000327	0.00126	CcSEcCtD
Dipyridamole—Angina pectoris—Epirubicin—testicular cancer	0.000326	0.00126	CcSEcCtD
Dipyridamole—PDE1A—Innate Immune System—BCL10—testicular cancer	0.000324	0.00161	CbGpPWpGaD
Dipyridamole—Diarrhoea—Dactinomycin—testicular cancer	0.000321	0.00124	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00032	0.00124	CcSEcCtD
Dipyridamole—Vomiting—Bleomycin—testicular cancer	0.00032	0.00124	CcSEcCtD
Dipyridamole—Hypotension—Etoposide—testicular cancer	0.000317	0.00123	CcSEcCtD
Dipyridamole—Rash—Bleomycin—testicular cancer	0.000317	0.00123	CcSEcCtD
Dipyridamole—Pain—Cisplatin—testicular cancer	0.000317	0.00122	CcSEcCtD
Dipyridamole—Dermatitis—Bleomycin—testicular cancer	0.000317	0.00122	CcSEcCtD
Dipyridamole—Hypersensitivity—Ifosfamide—testicular cancer	0.000317	0.00122	CcSEcCtD
Dipyridamole—PDE1B—Signaling by FGFR in disease—KIT—testicular cancer	0.000314	0.00156	CbGpPWpGaD
Dipyridamole—PDE1B—DAP12 interactions—KIT—testicular cancer	0.000314	0.00156	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by NGF—KITLG—testicular cancer	0.000314	0.00156	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by EGFR—KIT—testicular cancer	0.000311	0.00155	CbGpPWpGaD
Dipyridamole—Dysphagia—Doxorubicin—testicular cancer	0.00031	0.0012	CcSEcCtD
Dipyridamole—PDE1B—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000309	0.00153	CbGpPWpGaD
Dipyridamole—Asthenia—Ifosfamide—testicular cancer	0.000308	0.00119	CcSEcCtD
Dipyridamole—PDE1B—Signaling by PDGF—KIT—testicular cancer	0.000307	0.00153	CbGpPWpGaD
Dipyridamole—Feeling abnormal—Cisplatin—testicular cancer	0.000305	0.00118	CcSEcCtD
Dipyridamole—Paraesthesia—Etoposide—testicular cancer	0.000305	0.00118	CcSEcCtD
Dipyridamole—PDE1A—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000304	0.00151	CbGpPWpGaD
Dipyridamole—Pruritus—Ifosfamide—testicular cancer	0.000304	0.00118	CcSEcCtD
Dipyridamole—PDE1B—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000303	0.00151	CbGpPWpGaD
Dipyridamole—Dyspnoea—Etoposide—testicular cancer	0.000303	0.00117	CcSEcCtD
Dipyridamole—PDE6A—Disease—KITLG—testicular cancer	0.000302	0.0015	CbGpPWpGaD
Dipyridamole—PDE6B—Disease—KITLG—testicular cancer	0.000302	0.0015	CbGpPWpGaD
Dipyridamole—Somnolence—Etoposide—testicular cancer	0.000302	0.00117	CcSEcCtD
Dipyridamole—Angina pectoris—Doxorubicin—testicular cancer	0.000302	0.00117	CcSEcCtD
Dipyridamole—Nausea—Bleomycin—testicular cancer	0.000299	0.00115	CcSEcCtD
Dipyridamole—Vomiting—Dactinomycin—testicular cancer	0.000298	0.00115	CcSEcCtD
Dipyridamole—PDE1B—Innate Immune System—BCL10—testicular cancer	0.000297	0.00147	CbGpPWpGaD
Dipyridamole—Rash—Dactinomycin—testicular cancer	0.000296	0.00114	CcSEcCtD
Dipyridamole—Diarrhoea—Ifosfamide—testicular cancer	0.000294	0.00114	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Etoposide—testicular cancer	0.000293	0.00113	CcSEcCtD
Dipyridamole—Fatigue—Etoposide—testicular cancer	0.000293	0.00113	CcSEcCtD
Dipyridamole—PDE3B—Signaling Pathways—INSL3—testicular cancer	0.000292	0.00145	CbGpPWpGaD
Dipyridamole—Pain—Etoposide—testicular cancer	0.00029	0.00112	CcSEcCtD
Dipyridamole—Haemoglobin—Methotrexate—testicular cancer	0.000288	0.00111	CcSEcCtD
Dipyridamole—Haemorrhage—Methotrexate—testicular cancer	0.000286	0.00111	CcSEcCtD
Dipyridamole—Hepatitis—Methotrexate—testicular cancer	0.000286	0.00111	CcSEcCtD
Dipyridamole—Dizziness—Ifosfamide—testicular cancer	0.000284	0.0011	CcSEcCtD
Dipyridamole—Pharyngitis—Methotrexate—testicular cancer	0.000284	0.0011	CcSEcCtD
Dipyridamole—Feeling abnormal—Etoposide—testicular cancer	0.00028	0.00108	CcSEcCtD
Dipyridamole—Nausea—Dactinomycin—testicular cancer	0.000279	0.00108	CcSEcCtD
Dipyridamole—PDE1B—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000278	0.00138	CbGpPWpGaD
Dipyridamole—Gastrointestinal pain—Etoposide—testicular cancer	0.000278	0.00107	CcSEcCtD
Dipyridamole—ABCB1—lymph node—testicular cancer	0.000275	0.0016	CbGeAlD
Dipyridamole—PDE4A—Signaling Pathways—INSL3—testicular cancer	0.000274	0.00136	CbGpPWpGaD
Dipyridamole—Vomiting—Ifosfamide—testicular cancer	0.000273	0.00106	CcSEcCtD
Dipyridamole—Hypersensitivity—Cisplatin—testicular cancer	0.000273	0.00105	CcSEcCtD
Dipyridamole—PDE1C—Innate Immune System—FGFR3—testicular cancer	0.000273	0.00136	CbGpPWpGaD
Dipyridamole—Bradycardia—Epirubicin—testicular cancer	0.000273	0.00105	CcSEcCtD
Dipyridamole—Rash—Ifosfamide—testicular cancer	0.000271	0.00105	CcSEcCtD
Dipyridamole—Dermatitis—Ifosfamide—testicular cancer	0.000271	0.00105	CcSEcCtD
Dipyridamole—Urticaria—Etoposide—testicular cancer	0.00027	0.00104	CcSEcCtD
Dipyridamole—Haemoglobin—Epirubicin—testicular cancer	0.000269	0.00104	CcSEcCtD
Dipyridamole—Rhinitis—Epirubicin—testicular cancer	0.000269	0.00104	CcSEcCtD
Dipyridamole—Abdominal pain—Etoposide—testicular cancer	0.000268	0.00104	CcSEcCtD
Dipyridamole—Haemorrhage—Epirubicin—testicular cancer	0.000268	0.00103	CcSEcCtD
Dipyridamole—Hepatitis—Epirubicin—testicular cancer	0.000268	0.00103	CcSEcCtD
Dipyridamole—Tinnitus—Methotrexate—testicular cancer	0.000267	0.00103	CcSEcCtD
Dipyridamole—Hypoaesthesia—Epirubicin—testicular cancer	0.000266	0.00103	CcSEcCtD
Dipyridamole—PDE3A—Signaling Pathways—INSL3—testicular cancer	0.000266	0.00132	CbGpPWpGaD
Dipyridamole—Asthenia—Cisplatin—testicular cancer	0.000266	0.00103	CcSEcCtD
Dipyridamole—Pharyngitis—Epirubicin—testicular cancer	0.000266	0.00103	CcSEcCtD
Dipyridamole—Cardiac disorder—Methotrexate—testicular cancer	0.000266	0.00103	CcSEcCtD
Dipyridamole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000264	0.00131	CbGpPWpGaD
Dipyridamole—Angiopathy—Methotrexate—testicular cancer	0.00026	0.001	CcSEcCtD
Dipyridamole—Immune system disorder—Methotrexate—testicular cancer	0.000259	0.000999	CcSEcCtD
Dipyridamole—Mediastinal disorder—Methotrexate—testicular cancer	0.000258	0.000997	CcSEcCtD
Dipyridamole—Chills—Methotrexate—testicular cancer	0.000257	0.000992	CcSEcCtD
Dipyridamole—Nausea—Ifosfamide—testicular cancer	0.000255	0.000987	CcSEcCtD
Dipyridamole—PDE1A—Signaling by NGF—FGFR3—testicular cancer	0.000255	0.00127	CbGpPWpGaD
Dipyridamole—Diarrhoea—Cisplatin—testicular cancer	0.000254	0.00098	CcSEcCtD
Dipyridamole—Alopecia—Methotrexate—testicular cancer	0.000253	0.000977	CcSEcCtD
Dipyridamole—Bradycardia—Doxorubicin—testicular cancer	0.000252	0.000975	CcSEcCtD
Dipyridamole—PDE1C—Innate Immune System—KIT—testicular cancer	0.000251	0.00124	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—INSL3—testicular cancer	0.00025	0.00124	CbGpPWpGaD
Dipyridamole—Hypersensitivity—Etoposide—testicular cancer	0.00025	0.000966	CcSEcCtD
Dipyridamole—Tinnitus—Epirubicin—testicular cancer	0.00025	0.000965	CcSEcCtD
Dipyridamole—Haemoglobin—Doxorubicin—testicular cancer	0.000249	0.000962	CcSEcCtD
Dipyridamole—Flushing—Epirubicin—testicular cancer	0.000249	0.000961	CcSEcCtD
Dipyridamole—Cardiac disorder—Epirubicin—testicular cancer	0.000249	0.000961	CcSEcCtD
Dipyridamole—Rhinitis—Doxorubicin—testicular cancer	0.000248	0.00096	CcSEcCtD
Dipyridamole—Haemorrhage—Doxorubicin—testicular cancer	0.000248	0.000958	CcSEcCtD
Dipyridamole—Hepatitis—Doxorubicin—testicular cancer	0.000248	0.000958	CcSEcCtD
Dipyridamole—Hypoaesthesia—Doxorubicin—testicular cancer	0.000247	0.000953	CcSEcCtD
Dipyridamole—Pharyngitis—Doxorubicin—testicular cancer	0.000246	0.00095	CcSEcCtD
Dipyridamole—Dysgeusia—Methotrexate—testicular cancer	0.000244	0.000943	CcSEcCtD
Dipyridamole—Asthenia—Etoposide—testicular cancer	0.000244	0.000941	CcSEcCtD
Dipyridamole—Angiopathy—Epirubicin—testicular cancer	0.000243	0.000939	CcSEcCtD
Dipyridamole—Immune system disorder—Epirubicin—testicular cancer	0.000242	0.000935	CcSEcCtD
Dipyridamole—Mediastinal disorder—Epirubicin—testicular cancer	0.000241	0.000933	CcSEcCtD
Dipyridamole—Back pain—Methotrexate—testicular cancer	0.000241	0.000931	CcSEcCtD
Dipyridamole—Chills—Epirubicin—testicular cancer	0.00024	0.000929	CcSEcCtD
Dipyridamole—Pruritus—Etoposide—testicular cancer	0.00024	0.000928	CcSEcCtD
Dipyridamole—Arrhythmia—Epirubicin—testicular cancer	0.000239	0.000925	CcSEcCtD
Dipyridamole—Alopecia—Epirubicin—testicular cancer	0.000237	0.000915	CcSEcCtD
Dipyridamole—Vomiting—Cisplatin—testicular cancer	0.000236	0.00091	CcSEcCtD
Dipyridamole—PDE1A—Signaling by NGF—KIT—testicular cancer	0.000234	0.00116	CbGpPWpGaD
Dipyridamole—Rash—Cisplatin—testicular cancer	0.000234	0.000903	CcSEcCtD
Dipyridamole—Dermatitis—Cisplatin—testicular cancer	0.000233	0.000902	CcSEcCtD
Dipyridamole—PDE1B—Signaling by NGF—FGFR3—testicular cancer	0.000233	0.00116	CbGpPWpGaD
Dipyridamole—Diarrhoea—Etoposide—testicular cancer	0.000232	0.000898	CcSEcCtD
Dipyridamole—Ill-defined disorder—Methotrexate—testicular cancer	0.000231	0.000893	CcSEcCtD
Dipyridamole—Tinnitus—Doxorubicin—testicular cancer	0.000231	0.000893	CcSEcCtD
Dipyridamole—Anaemia—Methotrexate—testicular cancer	0.00023	0.00089	CcSEcCtD
Dipyridamole—PDE6B—Signaling Pathways—H2AFZ—testicular cancer	0.00023	0.00114	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—H2AFZ—testicular cancer	0.00023	0.00114	CbGpPWpGaD
Dipyridamole—Cardiac disorder—Doxorubicin—testicular cancer	0.00023	0.000889	CcSEcCtD
Dipyridamole—Flushing—Doxorubicin—testicular cancer	0.00023	0.000889	CcSEcCtD
Dipyridamole—Flatulence—Epirubicin—testicular cancer	0.00023	0.000888	CcSEcCtD
Dipyridamole—PDE1B—Signaling Pathways—INSL3—testicular cancer	0.000229	0.00114	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—STK11—testicular cancer	0.000229	0.00114	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—STK11—testicular cancer	0.000229	0.00114	CbGpPWpGaD
Dipyridamole—Tension—Epirubicin—testicular cancer	0.000229	0.000884	CcSEcCtD
Dipyridamole—Dysgeusia—Epirubicin—testicular cancer	0.000228	0.000882	CcSEcCtD
Dipyridamole—Nervousness—Epirubicin—testicular cancer	0.000226	0.000875	CcSEcCtD
Dipyridamole—Back pain—Epirubicin—testicular cancer	0.000226	0.000871	CcSEcCtD
Dipyridamole—Angiopathy—Doxorubicin—testicular cancer	0.000225	0.000869	CcSEcCtD
Dipyridamole—PDE6B—Disease—FGFR3—testicular cancer	0.000225	0.00112	CbGpPWpGaD
Dipyridamole—PDE6A—Disease—FGFR3—testicular cancer	0.000225	0.00112	CbGpPWpGaD
Dipyridamole—Malaise—Methotrexate—testicular cancer	0.000225	0.000868	CcSEcCtD
Dipyridamole—Dizziness—Etoposide—testicular cancer	0.000224	0.000867	CcSEcCtD
Dipyridamole—Muscle spasms—Epirubicin—testicular cancer	0.000224	0.000866	CcSEcCtD
Dipyridamole—Immune system disorder—Doxorubicin—testicular cancer	0.000224	0.000865	CcSEcCtD
Dipyridamole—Vertigo—Methotrexate—testicular cancer	0.000224	0.000865	CcSEcCtD
Dipyridamole—Mediastinal disorder—Doxorubicin—testicular cancer	0.000223	0.000863	CcSEcCtD
Dipyridamole—Chills—Doxorubicin—testicular cancer	0.000222	0.000859	CcSEcCtD
Dipyridamole—Arrhythmia—Doxorubicin—testicular cancer	0.000221	0.000855	CcSEcCtD
Dipyridamole—Nausea—Cisplatin—testicular cancer	0.00022	0.00085	CcSEcCtD
Dipyridamole—Alopecia—Doxorubicin—testicular cancer	0.000219	0.000846	CcSEcCtD
Dipyridamole—Cough—Methotrexate—testicular cancer	0.000217	0.00084	CcSEcCtD
Dipyridamole—Ill-defined disorder—Epirubicin—testicular cancer	0.000216	0.000836	CcSEcCtD
Dipyridamole—Convulsion—Methotrexate—testicular cancer	0.000216	0.000834	CcSEcCtD
Dipyridamole—Vomiting—Etoposide—testicular cancer	0.000216	0.000834	CcSEcCtD
Dipyridamole—Anaemia—Epirubicin—testicular cancer	0.000215	0.000833	CcSEcCtD
Dipyridamole—PDE1C—Disease—H2AFZ—testicular cancer	0.000215	0.00107	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by NGF—KIT—testicular cancer	0.000214	0.00106	CbGpPWpGaD
Dipyridamole—Rash—Etoposide—testicular cancer	0.000214	0.000827	CcSEcCtD
Dipyridamole—PDE1C—Immune System—KITLG—testicular cancer	0.000214	0.00106	CbGpPWpGaD
Dipyridamole—Dermatitis—Etoposide—testicular cancer	0.000214	0.000826	CcSEcCtD
Dipyridamole—Headache—Etoposide—testicular cancer	0.000213	0.000822	CcSEcCtD
Dipyridamole—Flatulence—Doxorubicin—testicular cancer	0.000213	0.000821	CcSEcCtD
Dipyridamole—Chest pain—Methotrexate—testicular cancer	0.000212	0.00082	CcSEcCtD
Dipyridamole—Myalgia—Methotrexate—testicular cancer	0.000212	0.00082	CcSEcCtD
Dipyridamole—Arthralgia—Methotrexate—testicular cancer	0.000212	0.00082	CcSEcCtD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000212	0.00105	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—H2AFZ—testicular cancer	0.000212	0.00105	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—KITLG—testicular cancer	0.000212	0.00105	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—KITLG—testicular cancer	0.000212	0.00105	CbGpPWpGaD
Dipyridamole—Tension—Doxorubicin—testicular cancer	0.000212	0.000818	CcSEcCtD
Dipyridamole—Dysgeusia—Doxorubicin—testicular cancer	0.000211	0.000816	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000211	0.000814	CcSEcCtD
Dipyridamole—Malaise—Epirubicin—testicular cancer	0.00021	0.000812	CcSEcCtD
Dipyridamole—Discomfort—Methotrexate—testicular cancer	0.00021	0.00081	CcSEcCtD
Dipyridamole—Nervousness—Doxorubicin—testicular cancer	0.00021	0.00081	CcSEcCtD
Dipyridamole—Vertigo—Epirubicin—testicular cancer	0.000209	0.000809	CcSEcCtD
Dipyridamole—Syncope—Epirubicin—testicular cancer	0.000209	0.000808	CcSEcCtD
Dipyridamole—Back pain—Doxorubicin—testicular cancer	0.000209	0.000806	CcSEcCtD
Dipyridamole—Muscle spasms—Doxorubicin—testicular cancer	0.000207	0.000801	CcSEcCtD
Dipyridamole—PDE6A—Disease—KIT—testicular cancer	0.000206	0.00102	CbGpPWpGaD
Dipyridamole—PDE6B—Disease—KIT—testicular cancer	0.000206	0.00102	CbGpPWpGaD
Dipyridamole—Palpitations—Epirubicin—testicular cancer	0.000206	0.000796	CcSEcCtD
Dipyridamole—Loss of consciousness—Epirubicin—testicular cancer	0.000205	0.000792	CcSEcCtD
Dipyridamole—Cough—Epirubicin—testicular cancer	0.000203	0.000786	CcSEcCtD
Dipyridamole—Anaphylactic shock—Methotrexate—testicular cancer	0.000203	0.000786	CcSEcCtD
Dipyridamole—Convulsion—Epirubicin—testicular cancer	0.000202	0.000781	CcSEcCtD
Dipyridamole—Nausea—Etoposide—testicular cancer	0.000202	0.000779	CcSEcCtD
Dipyridamole—Hypertension—Epirubicin—testicular cancer	0.000201	0.000778	CcSEcCtD
Dipyridamole—Ill-defined disorder—Doxorubicin—testicular cancer	0.0002	0.000773	CcSEcCtD
Dipyridamole—Nervous system disorder—Methotrexate—testicular cancer	0.000199	0.000771	CcSEcCtD
Dipyridamole—Anaemia—Doxorubicin—testicular cancer	0.000199	0.00077	CcSEcCtD
Dipyridamole—Thrombocytopenia—Methotrexate—testicular cancer	0.000199	0.000769	CcSEcCtD
Dipyridamole—Myalgia—Epirubicin—testicular cancer	0.000198	0.000767	CcSEcCtD
Dipyridamole—Chest pain—Epirubicin—testicular cancer	0.000198	0.000767	CcSEcCtD
Dipyridamole—Arthralgia—Epirubicin—testicular cancer	0.000198	0.000767	CcSEcCtD
Dipyridamole—Anxiety—Epirubicin—testicular cancer	0.000198	0.000764	CcSEcCtD
Dipyridamole—PDE1C—Disease—KITLG—testicular cancer	0.000198	0.000981	CbGpPWpGaD
Dipyridamole—Skin disorder—Methotrexate—testicular cancer	0.000198	0.000763	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000197	0.000762	CcSEcCtD
Dipyridamole—Hyperhidrosis—Methotrexate—testicular cancer	0.000197	0.00076	CcSEcCtD
Dipyridamole—Discomfort—Epirubicin—testicular cancer	0.000196	0.000758	CcSEcCtD
Dipyridamole—PDE8A—Signaling Pathways—H2AFZ—testicular cancer	0.000196	0.000972	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—H2AFZ—testicular cancer	0.000196	0.000972	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—KITLG—testicular cancer	0.000196	0.000971	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—KITLG—testicular cancer	0.000195	0.000967	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—STK11—testicular cancer	0.000195	0.000966	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—STK11—testicular cancer	0.000195	0.000966	CbGpPWpGaD
Dipyridamole—Malaise—Doxorubicin—testicular cancer	0.000195	0.000752	CcSEcCtD
Dipyridamole—Dry mouth—Epirubicin—testicular cancer	0.000194	0.00075	CcSEcCtD
Dipyridamole—Vertigo—Doxorubicin—testicular cancer	0.000194	0.000749	CcSEcCtD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000194	0.000962	CbGpPWpGaD
Dipyridamole—Syncope—Doxorubicin—testicular cancer	0.000193	0.000748	CcSEcCtD
Dipyridamole—PDE2A—Signaling Pathways—H2AFZ—testicular cancer	0.000191	0.000947	CbGpPWpGaD
Dipyridamole—Palpitations—Doxorubicin—testicular cancer	0.000191	0.000737	CcSEcCtD
Dipyridamole—Anaphylactic shock—Epirubicin—testicular cancer	0.00019	0.000735	CcSEcCtD
Dipyridamole—Oedema—Epirubicin—testicular cancer	0.00019	0.000735	CcSEcCtD
Dipyridamole—Hypotension—Methotrexate—testicular cancer	0.00019	0.000734	CcSEcCtD
Dipyridamole—PDE2A—Signaling Pathways—STK11—testicular cancer	0.00019	0.000941	CbGpPWpGaD
Dipyridamole—Loss of consciousness—Doxorubicin—testicular cancer	0.00019	0.000733	CcSEcCtD
Dipyridamole—PDE1A—Immune System—BCL10—testicular cancer	0.000189	0.000938	CbGpPWpGaD
Dipyridamole—Cough—Doxorubicin—testicular cancer	0.000188	0.000727	CcSEcCtD
Dipyridamole—Shock—Epirubicin—testicular cancer	0.000187	0.000723	CcSEcCtD
Dipyridamole—Convulsion—Doxorubicin—testicular cancer	0.000187	0.000722	CcSEcCtD
Dipyridamole—Nervous system disorder—Epirubicin—testicular cancer	0.000187	0.000721	CcSEcCtD
Dipyridamole—Thrombocytopenia—Epirubicin—testicular cancer	0.000186	0.00072	CcSEcCtD
Dipyridamole—Hypertension—Doxorubicin—testicular cancer	0.000186	0.00072	CcSEcCtD
Dipyridamole—Tachycardia—Epirubicin—testicular cancer	0.000186	0.000718	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000185	0.000716	CcSEcCtD
Dipyridamole—Skin disorder—Epirubicin—testicular cancer	0.000185	0.000714	CcSEcCtD
Dipyridamole—Hyperhidrosis—Epirubicin—testicular cancer	0.000184	0.000711	CcSEcCtD
Dipyridamole—Myalgia—Doxorubicin—testicular cancer	0.000184	0.00071	CcSEcCtD
Dipyridamole—Chest pain—Doxorubicin—testicular cancer	0.000184	0.00071	CcSEcCtD
Dipyridamole—Arthralgia—Doxorubicin—testicular cancer	0.000184	0.00071	CcSEcCtD
Dipyridamole—Anxiety—Doxorubicin—testicular cancer	0.000183	0.000707	CcSEcCtD
Dipyridamole—Paraesthesia—Methotrexate—testicular cancer	0.000183	0.000706	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000182	0.000705	CcSEcCtD
Dipyridamole—Discomfort—Doxorubicin—testicular cancer	0.000181	0.000701	CcSEcCtD
Dipyridamole—Dyspnoea—Methotrexate—testicular cancer	0.000181	0.0007	CcSEcCtD
Dipyridamole—Somnolence—Methotrexate—testicular cancer	0.000181	0.000698	CcSEcCtD
Dipyridamole—ADA—Metabolism—HPGDS—testicular cancer	0.00018	0.000896	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—KITLG—testicular cancer	0.00018	0.000894	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—KITLG—testicular cancer	0.00018	0.000894	CbGpPWpGaD
Dipyridamole—Dry mouth—Doxorubicin—testicular cancer	0.00018	0.000694	CcSEcCtD
Dipyridamole—Dyspepsia—Methotrexate—testicular cancer	0.000179	0.000692	CcSEcCtD
Dipyridamole—PDE1B—Innate Immune System—KITLG—testicular cancer	0.000179	0.000889	CbGpPWpGaD
Dipyridamole—Hypotension—Epirubicin—testicular cancer	0.000178	0.000687	CcSEcCtD
Dipyridamole—Anaphylactic shock—Doxorubicin—testicular cancer	0.000176	0.00068	CcSEcCtD
Dipyridamole—Oedema—Doxorubicin—testicular cancer	0.000176	0.00068	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000176	0.000678	CcSEcCtD
Dipyridamole—PDE2A—Signaling Pathways—KITLG—testicular cancer	0.000175	0.000871	CbGpPWpGaD
Dipyridamole—Fatigue—Methotrexate—testicular cancer	0.000175	0.000677	CcSEcCtD
Dipyridamole—PDE7B—Signaling Pathways—H2AFZ—testicular cancer	0.000174	0.000866	CbGpPWpGaD
Dipyridamole—Pain—Methotrexate—testicular cancer	0.000174	0.000672	CcSEcCtD
Dipyridamole—PDE7B—Signaling Pathways—STK11—testicular cancer	0.000173	0.000861	CbGpPWpGaD
Dipyridamole—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000173	0.00067	CcSEcCtD
Dipyridamole—Shock—Doxorubicin—testicular cancer	0.000173	0.000669	CcSEcCtD
Dipyridamole—PDE1B—Immune System—BCL10—testicular cancer	0.000173	0.000858	CbGpPWpGaD
Dipyridamole—Nervous system disorder—Doxorubicin—testicular cancer	0.000173	0.000667	CcSEcCtD
Dipyridamole—Thrombocytopenia—Doxorubicin—testicular cancer	0.000172	0.000666	CcSEcCtD
Dipyridamole—Tachycardia—Doxorubicin—testicular cancer	0.000172	0.000664	CcSEcCtD
Dipyridamole—Skin disorder—Doxorubicin—testicular cancer	0.000171	0.000661	CcSEcCtD
Dipyridamole—Paraesthesia—Epirubicin—testicular cancer	0.000171	0.00066	CcSEcCtD
Dipyridamole—Hyperhidrosis—Doxorubicin—testicular cancer	0.00017	0.000658	CcSEcCtD
Dipyridamole—Dyspnoea—Epirubicin—testicular cancer	0.00017	0.000656	CcSEcCtD
Dipyridamole—Somnolence—Epirubicin—testicular cancer	0.000169	0.000654	CcSEcCtD
Dipyridamole—Feeling abnormal—Methotrexate—testicular cancer	0.000168	0.000647	CcSEcCtD
Dipyridamole—Dyspepsia—Epirubicin—testicular cancer	0.000167	0.000647	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Methotrexate—testicular cancer	0.000166	0.000642	CcSEcCtD
Dipyridamole—Hypotension—Doxorubicin—testicular cancer	0.000165	0.000636	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000164	0.000635	CcSEcCtD
Dipyridamole—Fatigue—Epirubicin—testicular cancer	0.000164	0.000634	CcSEcCtD
Dipyridamole—Pain—Epirubicin—testicular cancer	0.000163	0.000629	CcSEcCtD
Dipyridamole—PDE11A—Signaling Pathways—H2AFZ—testicular cancer	0.000162	0.000805	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—H2AFZ—testicular cancer	0.000162	0.000805	CbGpPWpGaD
Dipyridamole—Urticaria—Methotrexate—testicular cancer	0.000162	0.000624	CcSEcCtD
Dipyridamole—PDE11A—Signaling Pathways—STK11—testicular cancer	0.000161	0.000801	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—STK11—testicular cancer	0.000161	0.000801	CbGpPWpGaD
Dipyridamole—Abdominal pain—Methotrexate—testicular cancer	0.000161	0.000621	CcSEcCtD
Dipyridamole—PDE7B—Signaling Pathways—KITLG—testicular cancer	0.00016	0.000797	CbGpPWpGaD
Dipyridamole—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00016	0.00062	CcSEcCtD
Dipyridamole—PDE1C—Immune System—FGFR3—testicular cancer	0.000159	0.000789	CbGpPWpGaD
Dipyridamole—Paraesthesia—Doxorubicin—testicular cancer	0.000158	0.000611	CcSEcCtD
Dipyridamole—PDE6A—Signaling Pathways—FGFR3—testicular cancer	0.000157	0.000781	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—FGFR3—testicular cancer	0.000157	0.000781	CbGpPWpGaD
Dipyridamole—Dyspnoea—Doxorubicin—testicular cancer	0.000157	0.000607	CcSEcCtD
Dipyridamole—Feeling abnormal—Epirubicin—testicular cancer	0.000157	0.000606	CcSEcCtD
Dipyridamole—Somnolence—Doxorubicin—testicular cancer	0.000157	0.000605	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Epirubicin—testicular cancer	0.000156	0.000601	CcSEcCtD
Dipyridamole—Dyspepsia—Doxorubicin—testicular cancer	0.000155	0.000599	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000152	0.000587	CcSEcCtD
Dipyridamole—Fatigue—Doxorubicin—testicular cancer	0.000152	0.000587	CcSEcCtD
Dipyridamole—Urticaria—Epirubicin—testicular cancer	0.000151	0.000584	CcSEcCtD
Dipyridamole—Pain—Doxorubicin—testicular cancer	0.000151	0.000582	CcSEcCtD
Dipyridamole—Abdominal pain—Epirubicin—testicular cancer	0.00015	0.000581	CcSEcCtD
Dipyridamole—PDE1C—Signaling Pathways—H2AFZ—testicular cancer	0.00015	0.000746	CbGpPWpGaD
Dipyridamole—Hypersensitivity—Methotrexate—testicular cancer	0.00015	0.000579	CcSEcCtD
Dipyridamole—PDE1C—Signaling Pathways—STK11—testicular cancer	0.000149	0.000742	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—KITLG—testicular cancer	0.000149	0.000741	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—KITLG—testicular cancer	0.000149	0.000741	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—H2AFZ—testicular cancer	0.000148	0.000736	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—STK11—testicular cancer	0.000147	0.000732	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—FGFR3—testicular cancer	0.000147	0.000729	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—KIT—testicular cancer	0.000146	0.000725	CbGpPWpGaD
Dipyridamole—Asthenia—Methotrexate—testicular cancer	0.000146	0.000564	CcSEcCtD
Dipyridamole—PDE1A—Innate Immune System—FGFR3—testicular cancer	0.000145	0.000722	CbGpPWpGaD
Dipyridamole—Feeling abnormal—Doxorubicin—testicular cancer	0.000145	0.000561	CcSEcCtD
Dipyridamole—PDE6G—Disease—FGFR3—testicular cancer	0.000145	0.000719	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—H2AFZ—testicular cancer	0.000145	0.000718	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—KIT—testicular cancer	0.000144	0.000717	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—KIT—testicular cancer	0.000144	0.000717	CbGpPWpGaD
Dipyridamole—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000144	0.000556	CcSEcCtD
Dipyridamole—Pruritus—Methotrexate—testicular cancer	0.000144	0.000556	CcSEcCtD
Dipyridamole—PDE10A—Signaling Pathways—STK11—testicular cancer	0.000144	0.000714	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000141	0.000699	CbGpPWpGaD
Dipyridamole—Hypersensitivity—Epirubicin—testicular cancer	0.00014	0.000542	CcSEcCtD
Dipyridamole—Urticaria—Doxorubicin—testicular cancer	0.00014	0.00054	CcSEcCtD
Dipyridamole—Abdominal pain—Doxorubicin—testicular cancer	0.000139	0.000538	CcSEcCtD
Dipyridamole—Diarrhoea—Methotrexate—testicular cancer	0.000139	0.000538	CcSEcCtD
Dipyridamole—PDE1C—Signaling Pathways—KITLG—testicular cancer	0.000138	0.000687	CbGpPWpGaD
Dipyridamole—Asthenia—Epirubicin—testicular cancer	0.000137	0.000528	CcSEcCtD
Dipyridamole—PDE6G—Signaling Pathways—KITLG—testicular cancer	0.000136	0.000677	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—KIT—testicular cancer	0.000135	0.000669	CbGpPWpGaD
Dipyridamole—Pruritus—Epirubicin—testicular cancer	0.000135	0.00052	CcSEcCtD
Dipyridamole—Dizziness—Methotrexate—testicular cancer	0.000134	0.00052	CcSEcCtD
Dipyridamole—PDE8B—Signaling Pathways—FGFR3—testicular cancer	0.000134	0.000664	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—FGFR3—testicular cancer	0.000134	0.000664	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—KIT—testicular cancer	0.000134	0.000663	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—FGFR3—testicular cancer	0.000133	0.00066	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—KITLG—testicular cancer	0.000133	0.00066	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—KIT—testicular cancer	0.000133	0.00066	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—STK11—testicular cancer	0.000131	0.000651	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—HPGDS—testicular cancer	0.000131	0.000651	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—FGFR3—testicular cancer	0.00013	0.000647	CbGpPWpGaD
Dipyridamole—Diarrhoea—Epirubicin—testicular cancer	0.00013	0.000503	CcSEcCtD
Dipyridamole—Hypersensitivity—Doxorubicin—testicular cancer	0.00013	0.000501	CcSEcCtD
Dipyridamole—Vomiting—Methotrexate—testicular cancer	0.000129	0.0005	CcSEcCtD
Dipyridamole—Rash—Methotrexate—testicular cancer	0.000128	0.000495	CcSEcCtD
Dipyridamole—Dermatitis—Methotrexate—testicular cancer	0.000128	0.000495	CcSEcCtD
Dipyridamole—Headache—Methotrexate—testicular cancer	0.000127	0.000492	CcSEcCtD
Dipyridamole—Asthenia—Doxorubicin—testicular cancer	0.000126	0.000488	CcSEcCtD
Dipyridamole—Dizziness—Epirubicin—testicular cancer	0.000126	0.000486	CcSEcCtD
Dipyridamole—Pruritus—Doxorubicin—testicular cancer	0.000125	0.000481	CcSEcCtD
Dipyridamole—PDE8A—Signaling Pathways—KIT—testicular cancer	0.000123	0.00061	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—KIT—testicular cancer	0.000123	0.00061	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—KIT—testicular cancer	0.000122	0.000606	CbGpPWpGaD
Dipyridamole—Vomiting—Epirubicin—testicular cancer	0.000121	0.000468	CcSEcCtD
Dipyridamole—Nausea—Methotrexate—testicular cancer	0.000121	0.000467	CcSEcCtD
Dipyridamole—Diarrhoea—Doxorubicin—testicular cancer	0.00012	0.000466	CcSEcCtD
Dipyridamole—Rash—Epirubicin—testicular cancer	0.00012	0.000464	CcSEcCtD
Dipyridamole—Dermatitis—Epirubicin—testicular cancer	0.00012	0.000463	CcSEcCtD
Dipyridamole—PDE2A—Signaling Pathways—KIT—testicular cancer	0.00012	0.000594	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—FGFR3—testicular cancer	0.000119	0.000592	CbGpPWpGaD
Dipyridamole—Headache—Epirubicin—testicular cancer	0.000119	0.000461	CcSEcCtD
Dipyridamole—Dizziness—Doxorubicin—testicular cancer	0.000116	0.00045	CcSEcCtD
Dipyridamole—PDE1A—Disease—H2AFZ—testicular cancer	0.000114	0.000568	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—H2AFZ—testicular cancer	0.000114	0.000568	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—KITLG—testicular cancer	0.000114	0.000566	CbGpPWpGaD
Dipyridamole—Nausea—Epirubicin—testicular cancer	0.000113	0.000437	CcSEcCtD
Dipyridamole—Vomiting—Doxorubicin—testicular cancer	0.000112	0.000433	CcSEcCtD
Dipyridamole—Rash—Doxorubicin—testicular cancer	0.000111	0.000429	CcSEcCtD
Dipyridamole—Dermatitis—Doxorubicin—testicular cancer	0.000111	0.000429	CcSEcCtD
Dipyridamole—PDE11A—Signaling Pathways—FGFR3—testicular cancer	0.000111	0.000551	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—FGFR3—testicular cancer	0.000111	0.000551	CbGpPWpGaD
Dipyridamole—Headache—Doxorubicin—testicular cancer	0.00011	0.000426	CcSEcCtD
Dipyridamole—PDE7B—Signaling Pathways—KIT—testicular cancer	0.000109	0.000544	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—KITLG—testicular cancer	0.000105	0.000522	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—KITLG—testicular cancer	0.000105	0.000522	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—H2AFZ—testicular cancer	0.000105	0.000519	CbGpPWpGaD
Dipyridamole—Nausea—Doxorubicin—testicular cancer	0.000105	0.000404	CcSEcCtD
Dipyridamole—PDE1B—Immune System—KITLG—testicular cancer	0.000104	0.000518	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—FGFR3—testicular cancer	0.000103	0.00051	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—KIT—testicular cancer	0.000102	0.000505	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—KIT—testicular cancer	0.000102	0.000505	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—FGFR3—testicular cancer	0.000101	0.000504	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—FGFR3—testicular cancer	9.88e-05	0.000491	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—KITLG—testicular cancer	9.62e-05	0.000478	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—STK11—testicular cancer	9.52e-05	0.000473	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—KIT—testicular cancer	9.44e-05	0.000469	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—H2AFZ—testicular cancer	9.35e-05	0.000464	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—KIT—testicular cancer	9.31e-05	0.000462	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—STK11—testicular cancer	9.3e-05	0.000462	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—KIT—testicular cancer	9.07e-05	0.00045	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—H2AFZ—testicular cancer	8.76e-05	0.000435	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—STK11—testicular cancer	8.71e-05	0.000432	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KITLG—testicular cancer	8.6e-05	0.000427	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—H2AFZ—testicular cancer	8.52e-05	0.000423	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—FGFR3—testicular cancer	8.47e-05	0.000421	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—STK11—testicular cancer	8.47e-05	0.000421	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KITLG—testicular cancer	8.06e-05	0.0004	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—H2AFZ—testicular cancer	8.01e-05	0.000398	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—STK11—testicular cancer	7.96e-05	0.000395	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KITLG—testicular cancer	7.84e-05	0.000389	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—FGFR3—testicular cancer	7.82e-05	0.000388	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—FGFR3—testicular cancer	7.82e-05	0.000388	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—KIT—testicular cancer	7.78e-05	0.000386	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—FGFR3—testicular cancer	7.75e-05	0.000385	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KITLG—testicular cancer	7.37e-05	0.000366	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—H2AFZ—testicular cancer	7.33e-05	0.000364	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—STK11—testicular cancer	7.28e-05	0.000362	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—KIT—testicular cancer	7.18e-05	0.000356	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—KIT—testicular cancer	7.18e-05	0.000356	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—FGFR3—testicular cancer	7.15e-05	0.000355	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—KIT—testicular cancer	7.11e-05	0.000353	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KITLG—testicular cancer	6.74e-05	0.000335	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—KIT—testicular cancer	6.57e-05	0.000326	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—FGFR3—testicular cancer	6.39e-05	0.000318	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—FGFR3—testicular cancer	5.99e-05	0.000297	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KIT—testicular cancer	5.87e-05	0.000292	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—FGFR3—testicular cancer	5.82e-05	0.000289	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KIT—testicular cancer	5.5e-05	0.000273	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—FGFR3—testicular cancer	5.48e-05	0.000272	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KIT—testicular cancer	5.35e-05	0.000266	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KIT—testicular cancer	5.03e-05	0.00025	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—FGFR3—testicular cancer	5.01e-05	0.000249	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KIT—testicular cancer	4.6e-05	0.000228	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—HPGDS—testicular cancer	3.6e-05	0.000179	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—STK11—testicular cancer	2.62e-05	0.00013	CbGpPWpGaD
